Project Grant R41NS143578
Award Date
7/8/25
Completion Date
4/30/27
Dollars Obligated
$350K
Federal Agency
National Institute of Neurological Disorders and Stroke
Awardee
Neurogt Inc. (NQHRNCAD21P3)
Federal Grant Program
93.853
Assistance Type
Project Grant
Place of Performance
North Carolina, USA
Similar Awards
This $1,369,242 project grant awarded by the National Institute of Neurological Disorders and Stroke (NINDS, CFDA 93.853) aims to develop an adeno-associated virus (AAV) gene therapy product for treating Mucopolysaccharidosis (MPS) IIIB, a rare lysosomal storage disease. The project focuses on optimizing and scaling up the manufacturing of the AAV9-based gene therapy product containing a codon-optimized human NAGLU cDNA. Phase I activities will involve engineering trials to develop and...
The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $803,958 Project Grant under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) to the Children's Hospital Medical Center in Cincinnati, Ohio. The grant funding supports the development of an innovative nanocarrier drug delivery system to enable stable and sustained delivery of a novel enzyme therapy to the brain for the treatment of neuronopathic Gaucher disease....
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program, is supporting the development of a first-in-class disease-modifying gene therapy for idiopathic Parkinson's disease (IDPD). The award provides $494,040 to Mark Therapeutics, Inc., a woman-owned small business, to conduct feasibility studies and rigorous preclinical...
This federal Project Grant award from the National Institutes of Health's Research Infrastructure Programs (CFDA 93.351) provides $156,136 to Recombinetics Inc. to advance gene therapy for Mucopolysaccharidosis Type IVA (MPS IVA), a rare lysosomal storage disease. The key products and services to be delivered under this award include: 1) Generating a porcine model of MPS IVA to serve as a valuable tool for understanding the disease biology and developing genetic therapies; 2) Conducting a...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program, provides $699,559 to Merlin Therapeutics Inc. to develop a novel adeno-associated viral vector 9 (AAV9) gene therapy for the treatment of neurofibromatosis type 2 (NF2). The therapy aims to express a healthy copy of the NF2 gene and rescue tumor characteristics in NF2...
The National Institute of Child Health and Human Development (NICHD) awarded a $295,923 Project Grant to Biostrategies LC under the Child Health and Human Development Extramural Research program (CFDA 93.865). The purpose of the award is to develop a "delivery-enhanced" gene therapy drug comprising an RTB:GALNS fusion protein for treating the rare metabolic disorder Mucopolysaccharidosis Type IVA (Morquio A Syndrome). The key objectives are to: 1) optimize the RTB:GALNS construct for...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, will support preclinical testing of a novel gene therapy for a rare pediatric neurodegenerative disease. The $419,482 award to the University of Texas Southwestern Medical Center will fund studies to determine the minimal effective dose and post-symptomatic treatment efficacy of the...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $461,701 to Tega Therapeutics Inc. to develop and validate an intracerebroventricular (ICV) enzyme replacement therapy for the treatment of GM1 gangliosidosis, a rare lysosomal storage disease affecting the central nervous system. The key objectives are to engineer cell lines to...
The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $226,500 Project Grant under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) to the University of Georgia Research Foundation, Inc. to characterize and treat peripheral nervous system dysfunction in Sanfilippo syndrome (mucopolysaccharidosis type IIIA). The project aims to develop novel cellular disease models using patient-derived induced pluripotent stem cells to...
This Project Grant award, provided by the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (CFDA 47.084) program, aims to advance gene therapy for neurological disorders by developing a scalable and cost-effective manufacturing process for extracellular vesicle (EV)-based therapeutics. The $304,951 award to Neucore Bio, Inc. will fund research to optimize methods for EV isolation, purification, and cargo loading to enhance therapeutic efficacy, with the goal...